Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$133,333.00

The Role of Self-Reactive, Epitope-Specific B Cells in the Pathogenesis of Systemic Lupus Erythematosus (SLE)

EF 2011-12

Résumé
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by the destruction of multiple organ systems by autoantibodies, which are antibodies that bind to the cells and tissues of patients with SLE. The specific "self" molecules targeted by autoantibodies are called autoantigens. To date, most research has focused on analyzing bulk populations of B cells in SLE and the autoantibodies they produce, yet little is known about rare autoreactive B cells that are specific for a single epitope, or region within an autoantigen. For my CIHR funded research, I will take advantage of a bank of blood samples from >400 SLE patients that is available to the Utz lab. I propose to 1) Employ state of the art technology developed in the Utz lab in collaboration with Intel, called silicon peptide microarray, to determine the precise epitopes within two known autoantigens, called U1-70K and histone H2B, that are targeted by the SLE patients' autoantibodies; 2) Generate molecular "tags" that will allow me to identify and purify B cells that make autoantibodies against these epitopes from the patients' blood samples; and 3) Utilize a new technology, called CyTOF, to analyze thousands of single epitope-specific B cells from the patients' blood samples, as well as the inflammatory molecules each cell expresses. The proposed studies will add to our understanding of how B cells contribute to the symptoms of SLE, and will identify the precise epitopes that SLE patients' autoantibodies recognize. If the epitopes were chemically joined to toxin molecules, they could serve as therapeutics to destroy autoreactive B cells. These studies will provide insights into ongoing clinical trials. This is particularly important given that one B cell targeted therapy was approved for treatment of SLE this year, and others recently entered human clinical trials. Further, epitope-specific B cells have the potential to serve as much needed diagnostics for SLE.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
242781
Name
Haddon David J
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
The Role of Self-Reactive, Epitope-Specific B Cells in the Pathogenesis of Systemic Lupus Erythematosus (SLE)
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$133,333
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Autoantibodies; Autoantigen Specific B Cells; Autoimmune; Cytof; Inflammation; Mctd; Protein Microarray; Proteomics; Systemic Lupus Erythematosus; Tetramer Analysis
Abstract
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by the destruction of multiple organ systems by autoantibodies, which are antibodies that bind to the cells and tissues of patients with SLE. The specific "self" molecules targeted by autoantibodies are called autoantigens. To date, most research has focused on analyzing bulk populations of B cells in SLE and the autoantibodies they produce, yet little is known about rare autoreactive B cells that are specific for a single epitope, or region within an autoantigen. For my CIHR funded research, I will take advantage of a bank of blood samples from >400 SLE patients that is available to the Utz lab. I propose to 1) Employ state of the art technology developed in the Utz lab in collaboration with Intel, called silicon peptide microarray, to determine the precise epitopes within two known autoantigens, called U1-70K and histone H2B, that are targeted by the SLE patients' autoantibodies; 2) Generate molecular "tags" that will allow me to identify and purify B cells that make autoantibodies against these epitopes from the patients' blood samples; and 3) Utilize a new technology, called CyTOF, to analyze thousands of single epitope-specific B cells from the patients' blood samples, as well as the inflammatory molecules each cell expresses. The proposed studies will add to our understanding of how B cells contribute to the symptoms of SLE, and will identify the precise epitopes that SLE patients' autoantibodies recognize. If the epitopes were chemically joined to toxin molecules, they could serve as therapeutics to destroy autoreactive B cells. These studies will provide insights into ongoing clinical trials. This is particularly important given that one B cell targeted therapy was approved for treatment of SLE this year, and others recently entered human clinical trials. Further, epitope-specific B cells have the potential to serve as much needed diagnostics for SLE.
Competitiondate
201110
Approvedterm2
2 yrs 8 mths
Pinamesdelim
Haddon, David J
Approvedterm
2 ans 8 mois
Cihrcontribution2
~ $133,333~ $0~